EC approves Merck’s KEYTRUDA regimen for NSCLC treatment
29 Mar 2024
Phase 3Clinical ResultDrug Approval
Preview
Source: Pharmaceutical Technology
With the EC approval, Merck’s KEYTRUDA treatment can be marketed for NSCLC treatment across all 27 EU member states. Credit: Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
The European Commission (EC) has approved Merck’s KEYTRUDA regimen for treating adult patients with resectable non-small cell lung cancer (NSCLC) at increased recurrence risk.
This approval follows the Committee for Medicinal Products for Human Use positive recommendation in February this year.
KEYTRUDA, indicated for usage in combination with platinum-containing chemotherapy, will serve as a neoadjuvant treatment and continue as monotherapy for adjuvant treatment.
The EC’s decision is based on the double-blind, randomised Phase III KEYNOTE-671 trial outcomes.
The trial enrolled 797 patients with event-free survival (EFS) and overall survival (OS) as the dual primary endpoints of the trial.
See Also:
Preview
Source: Pharmaceutical Technology
Atea Pharmaceuticals gets grant for treatment of covid-19 using purine nucleotide phosphoramidates
Preview
Source: Pharmaceutical Technology
At a median follow-up of 29.8 months, results showed a 28% reduction in the mortality risk and a 41% decrease in the disease recurrence, progression, or mortality risk in patients treated with the KEYTRUDA-based regimen.
The median OS for patients receiving KEYTRUDA was notably higher than for those on the chemotherapy-placebo regimen, with the former not yet reached versus 52.4 months for the latter.
With this approval, the KEYTRUDA regimen can be marketed for this indication across all 27 EU member states, as well as in Liechtenstein, Iceland, Norway, and Northern Ireland.
Merck Research Laboratories global clinical development, oncology senior vice-president and head Marjorie Green said: “The approval of the first anti-PD-1/L1 therapy as part of a treatment regimen in Europe for the neoadjuvant followed by adjuvant treatment of resectable NSCLC based on positive overall survival results demonstrates our continued progress to advance treatments in earlier stages of lung cancer.
“We are eager to build on this momentum as we plan to seek additional approvals of this regimen around the world, and to work together with the cancer community to help drive earlier diagnoses of lung cancer, an urgent need.”
The US Food and Drug Administration (FDA) granted approval to Merck’s sotatercept-csrk, known by the brand name WINREVAIR, for pulmonary arterial hypertension (PAH).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.